28078046|t|Effects of etomidate and propofol on immune function in patients with lung adenocarcinoma
28078046|a|To investigate the effects of etomidate and propofol on immune function in patients with lung adenocarcinoma. Sixty patients who were scheduled for lung cancer surgery under general anesthesia were studied. The patients were randomly divided into an etomidate total intravenous anesthesia group (group E) and a propofol total intravenous anesthesia group (group P), with 30 cases in each group. Within group comparison: The percentage of CD4+ in the two groups was significantly reduced at 24 hours post-operation (T2) compared with the percentage before surgery, whereas the percentage of CD8+ was higher at T2. Between group comparison: The CD4+ percentage of group E was higher than that of group P (P < 0.05) at T2, whereas the CD8+ percentage was lower than that of group P (P < 0.05) at T1. Using etomidate for anesthesia has less of an effect on immune function in patients with lung adenocarcinoma.
28078046	0	7	Effects	T080	C1280500
28078046	11	20	etomidate	T109,T121	C0015131
28078046	25	33	propofol	T109,T121	C0033487
28078046	37	52	immune function	T042	C1817756
28078046	56	64	patients	T101	C0030705
28078046	70	89	lung adenocarcinoma	T191	C0152013
28078046	93	104	investigate	T169	C1292732
28078046	109	119	effects of	T080	C1704420
28078046	120	129	etomidate	T109,T121	C0015131
28078046	134	142	propofol	T109,T121	C0033487
28078046	146	161	immune function	T042	C1817756
28078046	165	173	patients	T101	C0030705
28078046	179	198	lung adenocarcinoma	T191	C0152013
28078046	200	205	Sixty	T081	C3816724
28078046	206	214	patients	T101	C0030705
28078046	224	233	scheduled	T080	C0205539
28078046	238	257	lung cancer surgery	T061	C0920424
28078046	264	282	general anesthesia	T061	C0002915
28078046	288	295	studied	T062	C2603343
28078046	301	309	patients	T101	C0030705
28078046	340	349	etomidate	T109,T121	C0015131
28078046	350	378	total intravenous anesthesia	T061	C0473965
28078046	379	384	group	T101	C0030705
28078046	386	393	group E	T101	C0030705
28078046	401	409	propofol	T109,T121	C0033487
28078046	410	438	total intravenous anesthesia	T061	C0473965
28078046	439	444	group	T101	C0030705
28078046	446	453	group P	T101	C0030705
28078046	464	469	cases	T169	C0868928
28078046	473	477	each	T081	C1457900
28078046	478	483	group	T101	C0030705
28078046	492	497	group	T101	C0030705
28078046	498	508	comparison	T052	C1707455
28078046	514	532	percentage of CD4+	T059	C1277791
28078046	540	543	two	T081	C0205448
28078046	544	550	groups	T101	C0030705
28078046	569	576	reduced	T080	C0392756
28078046	583	588	hours	T079	C0439227
28078046	589	603	post-operation	T079	C0032790
28078046	605	607	T2	T079	C0032790
28078046	609	617	compared	T052	C1707455
28078046	627	637	percentage	T059	C1277791
28078046	638	644	before	T079	C0332152
28078046	645	652	surgery	T061	C0543467
28078046	666	695	percentage of CD8+ was higher	T033	C4285770
28078046	699	701	T2	T079	C0032790
28078046	711	716	group	T101	C0030705
28078046	717	727	comparison	T052	C1707455
28078046	733	748	CD4+ percentage	T059	C1277791
28078046	752	759	group E	T101	C0030705
28078046	764	770	higher	T081	C1561957
28078046	784	791	group P	T101	C0030705
28078046	806	808	T2	T079	C0032790
28078046	822	847	CD8+ percentage was lower	T033	C4285769
28078046	861	868	group P	T101	C0030705
28078046	883	885	T1	T079	C0032790
28078046	893	902	etomidate	T109,T121	C0015131
28078046	907	917	anesthesia	T121	C4049933
28078046	922	926	less	T081	C0439092
28078046	933	939	effect	T080	C1280500
28078046	943	958	immune function	T042	C1817756
28078046	962	970	patients	T101	C0030705
28078046	976	995	lung adenocarcinoma	T191	C0152013